BeOne MedicinesSHSE:688235 +3.86%70 Future 3-5Y EPS without NRI Growth Rate is 73.40 as of Jun. 24, 2026. GuruFocus rates SHSE:688235 with a GF Score™ of 70/100 and a GF Value™ of ¥313.72 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 402 Biotechnology companies, BeOne Medicines ranks better than 96.52% on this metric.
Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
As of today, BeOne Medicines's Future 3-5Y EPS without NRI Growth Rate is 73.40.
Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.
BeOne Medicines Future 3-5Y EPS without NRI Growth Rate Related Terms
SHSE:688235 vs RVMD, RPRX, BNTX: Future 3-5Y EPS without NRI Growth Rate Comparison
For the Biotechnology subindustry, BeOne Medicines's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeOne Medicines Future 3-5Y EPS without NRI Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeOne Medicines's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:
* The bar in red indicates where BeOne Medicines's Future 3-5Y EPS without NRI Growth Rate falls into.
What does a Future 3-5Y EPS without NRI Growth Rate of 73.40 mean?
BeOne Medicines (SHSE:688235) has a Future 3-5Y EPS without NRI Growth Rate of 73.40 as of Jun. 24, 2026. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for BeOne Medicines and its competitors. According to the industry distribution chart, BeOne Medicines ranks #14 out of 402 companies in the Biotechnology industry, placing it in the top 3.5%.
Is BeOne Medicines' Future 3-5Y EPS without NRI Growth Rate too high?
BeOne Medicines' current Future 3-5Y EPS without NRI Growth Rate is 73.40. The Biotechnology industry median Future 3-5Y EPS without NRI Growth Rate is 20.49. BeOne Medicines' value of 73.40 is 258.2% above this industry median. Based on the distribution chart, BeOne Medicines ranks #14 out of 402 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, BeOne Medicines has a GF Score™ of 70/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does BeOne Medicines' Future 3-5Y EPS without NRI Growth Rate compare to RVMD and RPRX?
According to the Biotechnology industry distribution chart, BeOne Medicines ranks #14 out of 402 companies for Future 3-5Y EPS without NRI Growth Rate. This places BeOne Medicines in the top 4% of its industry — outperforming the majority of peers. The industry median Future 3-5Y EPS without NRI Growth Rate is 20.49. BeOne Medicines' value of 73.40 is 258.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Future 3-5Y EPS without NRI Growth Rate for a Biotechnology company?
The median Future 3-5Y EPS without NRI Growth Rate among Biotechnology companies is 20.49, based on 402 companies in the industry. Companies in the top quartile (top 25%) have a Future 3-5Y EPS without NRI Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, Future 3-5Y EPS without NRI Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BeOne Medicines's current Future 3-5Y EPS without NRI Growth Rate of 73.40 is 258.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Future 3-5Y EPS without NRI Growth Rate mean?
A high Future 3-5Y EPS without NRI Growth Rate can signal that a stock is expensive relative to its fundamentals. EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period. View historical data for BeOne Medicines and its competitors. For the Biotechnology industry, the median Future 3-5Y EPS without NRI Growth Rate is 20.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BeOne Medicines's current Future 3-5Y EPS without NRI Growth Rate is 73.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeOne Medicines stock overvalued right now?
Based on GuruFocus' analysis, BeOne Medicines (SHSE:688235) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥313.72, compared to a current price of ¥236.79 — trading 24.5% below its estimated fair value. The current Future 3-5Y EPS without NRI Growth Rate is 73.40 and 258.2% above the Biotechnology industry median of 20.49. BeOne Medicines' overall GF Score™ is 70/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Future 3-5Y EPS without NRI Growth Rate calculated?
Future 3-5Y EPS without NRI Growth Rate is calculated from a company's financial statements. For BeOne Medicines (SHSE:688235), the current Future 3-5Y EPS without NRI Growth Rate is 73.40 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BeOne Medicines (SHSE:688235) Overvalued in 2026?
Based on GuruFocus' analysis, BeOne Medicines stock appears to be undervalued.
The current stock price of ¥236.79 is trading 24.5% below its estimated GF Value™ of ¥313.72.
GuruFocus considers BeOne Medicines to be Modestly Undervalued.
Key valuation signals for SHSE:688235:
Future 3-5Y EPS without NRI Growth Rate: 73.40
GF Value™: ¥313.72 vs. price of ¥236.79 (24.5% below fair value)
Industry Position: 258.2% above the Biotechnology median (#14 of 402)
No single metric tells the full story. See the SHSE:688235 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
70GF Score
Get the complete analysis for SHSE:688235
Future 3-5Y EPS without NRI Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688235 has been successfully added to your 